AI summary by TwinMind

Why useless decongestants are still for sale

Vox

9m 52s

Background: Decongestant Market Evolution

  • Sudafed vs Sudafed PE comparison: pseudoephedrine vs phenylephrine
  • Phenylephrine vastly outsells pseudoephedrine today despite ineffectiveness
  • Personal experience: daily phenylephrine use with no relief

FDA's Historical Regulatory Framework (1962-1990s)

  • 1962: FDA charged with reviewing safety/effectiveness of drugs
  • Started with prescription drugs first due to higher concern
  • 1972: OTC review began for massive shelf (100,000-500,000 products)
  • Too many products for thorough review
  • Grandfathered existing ingredients if "generally recognized as safe and effective"
  • 1976: Panel recommended three nasal decongestants:
    • Phenylephrine (red - ineffective)
    • Pseudoephedrine (blue - effective)
    • Phenylpropanolamine (grey - later removed)
  • 1990s: List further codified
  • Pseudoephedrine became dominant OTC decongestant through 80s-90s

The Methamphetamine Problem (2005)

  • Pseudoephedrine essential ingredient for making methamphetamine
  • 2005: Combat Methamphetamine Act (attached to Patriot Act)
  • Pseudoephedrine moved behind pharmacy counter
  • Required ID verification and purchase limits
  • Phenylpropanolamine removed by 2000 due to hemorrhagic stroke risk
  • Phenylephrine left alone on shelves
  • Companies like Pfizer created "PE" versions (Sudafed PE)
  • Phenylephrine sales began exceeding pseudoephedrine

Early Evidence of Ineffectiveness (2006)

  • 2006 headline: "Sudafed's replacement no winner"
  • Florida researcher received calls about phenylephrine not working
  • Study found: "oral phenylephrine is ineffective as nasal decongestant but safe"
  • Most effectiveness studies came from single lab: Elizabeth Biochemical
  • Congressional support from Representative Henry Waxman
  • Further studies confirmed ineffectiveness

Regulatory Obstacles and Delays (2006-2023)

  • Dr. Janet Woodcock (FDA Center for Drug Evaluation): burdensome multi-step rulemaking process
  • Process "frozen in 1972 and before"
  • No innovation pathway for OTC drugs
  • Significantly smaller funding for OTC division vs prescription drugs
  • 2020 CARES Act: provided more tools and resources for OTC division
  • Made drug amendments slightly easier

2023 FDA Panel Review

  • Advisory panel reviewed new studies with clear data
  • Charts showed:
    • Nasal congestion decreased with pseudoephedrine
    • No improvement with phenylephrine (similar to placebo)
  • Panel votes against phenylephrine effectiveness
  • Panel mystified by phenylephrine market dominance

Panel Member Reactions

  • "Amazing amount of dollars spent on something with no efficacy"
  • Medical professionals unaware of limited data despite training
  • "Drug companies made billions off this medication for years"
  • Concerns about changing pharmacy aisle layouts
  • Unanimous recommendation against effectiveness

Current Status and Producer Note

  • FDA panel vote is recommendation requiring FDA implementation
  • Producer Phil Edwards explains Vox's free journalism mission
  • Request for contributions at vox.com/give-now
  • Recurring contributors get newsletters and behind-the-scenes access

TwinMind

Get summaries like this for your own meetings

TwinMind takes notes in the background during meetings, lectures, and calls, then writes the summary for you.

Free plan to get started

No bot joins your calls

Phone, desktop & Chrome apps

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome